Belite Bio
BLTE

Belite Bio (BLTE) earnings history

Most recent quarter

Period end
Jun 30, 2026
EPS actual
−$0.70
EPS estimate
−$0.78
Revenue
$0.00
Reported
Aug 13, 2026

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2026Aug 13, 2026−$0.78−$0.70+9.89%$0.00SEC
Q1 2026May 20, 2026−$0.63−$0.34+46.45%$0.00SEC
Q4 2025Mar 2, 2026−$0.55−$0.38+30.44%$0.00SEC
Q3 2025Nov 10, 2025−$0.49−$0.65−33.33%$0.00SEC
Q2 2025Aug 11, 2025−$0.41−$0.50−21.95%$0.00SEC
Q1 2025May 14, 2025−$0.35−$0.45−27.84%$0.00SEC
Q4 2024Mar 17, 2025−$0.31−$0.32−3.90%$0.00SEC
Q3 2024Nov 12, 2024−$0.29−$0.28+2.78%$0.00SEC
Q2 2024Aug 9, 2024−$0.26−$0.31−21.09%$0.00SEC
Q1 2024May 14, 2024−$0.29−$0.27+5.26%$0.00SEC
Q4 2023Mar 12, 2024−$0.30−$0.25+16.67%$0.00SEC
Q3 2023Nov 14, 2023−$0.32−$0.40−25.00%$0.00SEC
Q2 2023Aug 9, 2023−$0.30−$0.26+12.61%$0.00SEC
Q1 2023May 11, 2023−$0.20−$0.33−65.00%$0.00SEC

Quarterly revenue

Q1 2023
$0.00
Q2 2023
$0.00
Q3 2023
$0.00
Q4 2023
$0.00
Q1 2024
$0.00
Q2 2024
$0.00
Q3 2024
$0.00
Q4 2024
$0.00
Q1 2025
$0.00
Q2 2025
$0.00
Q3 2025
$0.00
Q4 2025
$0.00
Q1 2026
$0.00
Q2 2026
$0.00

Frequently asked questions

  • When did Belite Bio (BLTE) last report earnings?

    Belite Bio last reported on Aug 13, 2026, covering fiscal Q2 2026.

  • Did BLTE beat earnings estimates?

    Yes. Belite Bio reported EPS of −$0.70 for Q2 2026 against a −$0.78 estimate — a 9.89% beat.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.